If you invest in bio-tech you should consider Amarantus Bioscience -AMBS - currently under a dime.
The company recently launched its diagnostic test, LymPro, that detects early stage Alzheimer's. Potential $3B annual market.
The company also has several orphan indications for its patented drug MANF.
Read yesterday's Yahoo news for AMBS.
Amarantus Bioscience - AMBS - Currently trading under a dime.
Partnership for the company's diagnostic blood test to detect early stage Alzheimer's expected to be announced soon. Potential $500M annual market with no competition.
Twitter: @AmarantusBio .... 10,000 followers.
Not surprising that there was profit taking today especially when there was no news.
The short volume yesterday was over 5,000,000 shares and I would imagine today's was comparable.
Over 13,000,000 shares traded today and it almost closed at .08 which is almost double what it was a few weeks ago.
The stock continues to be under accumulaion as word gets out to the market.
2014 will be a very good year for the AMBS shareholders.
As Ripley said, "Believe it or not?"
If he's correct the share price goes to .50.
Place your bets.
Jason Napadano rates it's a "BUY" and his price target offers 400% upside.
Currently trading under a dime with a $25M market cap.
China continues to accumulate gold as it plans for the Yuan to replace the dollar as the world standard currency.
The Yuan recently surpassed the Euro and moved into second place as the currency used most in global trade transactions.
Gold is at a bottom here.
The company and its potential is still unknown to the vast number of potential shareholders. Word is getting out gradually.
So much potential for less than a dime a share.
Most of the tax loss selling has already taken place and those individuals are looking for a reason to re buy their positions. This may be the catalyst to get many of them to do so tomorrow. A ten percent move to the upside this week wouldn't surprise me.
I suggest you cover your short position.